A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects With Metastatic Gastric Cancer
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Foretinib (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 25 Dec 2009 Actual end date (1 Nov 2009) added as reported by ClinicalTrials.gov.
- 25 Dec 2009 Actual end date (1 Nov 2009) added as reported by ClinicalTrials.gov.
- 25 Dec 2009 Actual patient number (74) added as reported by ClinicalTrials.gov.